MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target
- PMID: 29196609
- DOI: 10.1042/BST20170037
MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs of ∼22 nucleotides, which have increasingly been recognized as potent post-transcriptional regulators of gene expression. MiRNA targeting is defined by the complementarities between positions 2-8 of miRNA 5'-end with generally the 3'-untranslated region of target mRNAs (messenger RNAs). The capacity of miRNAs to simultaneously inhibit many different mRNAs allows for an amplification of biological responses. Hence, miRNAs are extremely attractive targets for therapeutic regulation in several diseases, including cardiovascular. Novel approaches are emerging to identify the miRNA functions in cardiovascular biology processes and to improve miRNA delivery in the heart and vasculature. In the present study, we provide an overview of current studies of miRNA functions in cardiovascular cells by the use of high-content screening. We also discuss the challenge to achieve a safe and targeted delivery of miRNA therapeutics in cardiovascular cells.
Keywords: cardiovascular disease; gene therapy; high-throughput screening; microRNA.
© 2018 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.
Similar articles
-
Identification of cardiovascular microRNA targetomes.J Mol Cell Cardiol. 2011 Nov;51(5):674-81. doi: 10.1016/j.yjmcc.2011.08.017. Epub 2011 Aug 24. J Mol Cell Cardiol. 2011. PMID: 21888912 Review.
-
Progress in microRNA delivery.J Control Release. 2013 Dec 28;172(3):962-74. doi: 10.1016/j.jconrel.2013.09.015. Epub 2013 Sep 25. J Control Release. 2013. PMID: 24075926 Free PMC article. Review.
-
Therapeutic advances in MicroRNA targeting.J Cardiovasc Pharmacol. 2011 Jan;57(1):1-7. doi: 10.1097/FJC.0b013e3181f603d0. J Cardiovasc Pharmacol. 2011. PMID: 20729755 Review.
-
miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart.Future Med Chem. 2015;7(13):1771-92. doi: 10.4155/fmc.15.107. Epub 2015 Sep 24. Future Med Chem. 2015. PMID: 26399457 Review.
-
Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges.Clin Sci (Lond). 2014 Sep;127(6):351-65. doi: 10.1042/CS20140005. Clin Sci (Lond). 2014. PMID: 24895056 Review.
Cited by
-
Non-Coding RNAs in Kidney Stones.Biomolecules. 2024 Feb 11;14(2):213. doi: 10.3390/biom14020213. Biomolecules. 2024. PMID: 38397450 Free PMC article. Review.
-
MicroRNAs in Myocarditis-Review of the Preclinical In Vivo Trials.Biomedicines. 2023 Oct 8;11(10):2723. doi: 10.3390/biomedicines11102723. Biomedicines. 2023. PMID: 37893097 Free PMC article. Review.
-
Using RNA-based therapies to target the kidney in cardiovascular disease.Front Cardiovasc Med. 2023 Oct 6;10:1250073. doi: 10.3389/fcvm.2023.1250073. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37868774 Free PMC article. Review.
-
Emerging roles of microRNAs in septic cardiomyopathy.Front Pharmacol. 2023 Jul 5;14:1181372. doi: 10.3389/fphar.2023.1181372. eCollection 2023. Front Pharmacol. 2023. PMID: 37475718 Free PMC article. Review.
-
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy.Front Oncol. 2023 Jun 16;13:1155254. doi: 10.3389/fonc.2023.1155254. eCollection 2023. Front Oncol. 2023. PMID: 37397377 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources

